Literature DB >> 25220697

Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients.

Zhiqiang Song1, Jianzhong Zhang2, Lihua He2, Minhu Chen3, Xiaohua Hou4, Zhaoshen Li5, Liya Zhou6.   

Abstract

BACKGROUND: Large-scale multi-region studies are urgently needed to provide comprehensive and up-to-date information on the antibiotic resistance of Helicobacter pylori that is critical for selecting the most optimal eradication regimens. AIMS: To determine the resistance patterns of Helicobacter pylori strains isolated from dyspeptic patients.
METHODS: This is a prospective, multicentre, cross-sectional, observational study. Helicobacter pylori cultures were successful in 600 patients (never receiving eradication therapy) from Northern, Eastern, Middle, and Southern regions between 2008 and 2012. Resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and rifampicin was determined by Epsilometer test.
RESULTS: The overall resistance rate was highest for metronidazole (403, 67.2%), followed by clarithromycin (225, 37.5%), levofloxacin (201, 33.5%), rifampicin (85, 14.2%), amoxicillin (41, 6.8%), and tetracycline (21, 3.5%). There were 16.3% isolates susceptible to all tested antibiotics, followed by mono-resistance (34.2%), double resistance (27.0%), triple resistance (16.8%), quadruple resistance (4.7%), quintuple resistance (0.7%) and sextuple resistance (0.3%). Independent factors influencing antibiotic resistance were gender (to levofloxacin), age (to levofloxacin), and endoscopic finding (to clarithromycin, metronidazole, and levofloxacin). Among the clarithromycin-resistant isolates, 75.6% and 48.0% were also resistant to metronidazole and levofloxacin, respectively.
CONCLUSIONS: Helicobacter pylori resistance to commonly used antibiotics in China is a very serious issue, due to the high resistance rate and general multiple resistance.
Copyright © 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; China; Helicobacter pylori

Mesh:

Substances:

Year:  2014        PMID: 25220697     DOI: 10.1016/j.dld.2014.08.038

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  13 in total

Review 1.  Innovative Perspectives of Integrated Chinese Medicine on H. pylori.

Authors:  Hui Ye; Zong-Ming Shi; Yao Chen; Jing Yu; Xue-Zhi Zhang
Journal:  Chin J Integr Med       Date:  2018-06-08       Impact factor: 1.978

Review 2.  Primary Antibiotic Resistance of Helicobacter pylori in China.

Authors:  Yi Hu; Yin Zhu; Nong-Hua Lu
Journal:  Dig Dis Sci       Date:  2017-03-17       Impact factor: 3.199

3.  Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.

Authors:  Wei Fu; Zhiqiang Song; Liya Zhou; Yan Xue; Yu Ding; Baojun Suo; Xueli Tian; Li Wang
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

4.  Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients.

Authors:  Yongfu Shao; Rongdan Lu; Yunben Yang; Qiancheng Xu; Bojun Wang; Guoliang Ye
Journal:  J Clin Lab Anal       Date:  2017-10-06       Impact factor: 2.352

Review 5.  Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.

Authors:  Yi Hu; Yin Zhu; Nong-Hua Lu
Journal:  Front Cell Infect Microbiol       Date:  2017-05-05       Impact factor: 5.293

6.  Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.

Authors:  Bei Tan; Han-Qing Luo; Hong Xu; Nong-Hua Lv; Rui-Hua Shi; He-Sheng Luo; Jian-Sheng Li; Jian-Lin Ren; Yi-You Zou; Yan-Qing Li; Feng Ji; Jing-Yuan Fang; Jia-Ming Qian
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

7.  CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication.

Authors:  Tsung-Jung Lin; Hsi-Chang Lee; Chih-Lin Lin; Chung-Kwe Wang; Kuan-Yang Chen; Deng-Chyang Wu
Journal:  World J Clin Cases       Date:  2018-10-26       Impact factor: 1.337

8.  Study on the value of antibiotic-resistant gene detection in Helicobacter pylori in China.

Authors:  Jinfeng Dai; Jing Zhao; Liqi Mao; Yue Hu; Bin Lv
Journal:  Exp Ther Med       Date:  2022-01-18       Impact factor: 2.447

Review 9.  Hybrid Therapy Regimen for Helicobacter Pylori Eradication.

Authors:  Zhi-Qiang Song; Jian Liu; Li-Ya Zhou
Journal:  Chin Med J (Engl)       Date:  2016-04-20       Impact factor: 2.628

10.  Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study.

Authors:  Wen Gao; Hui Ye; Xin Deng; Chi Wang; Ying Xu; Yixuan Li; Xuezhi Zhang; Hong Cheng
Journal:  Helicobacter       Date:  2020-06-16       Impact factor: 5.753

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.